NEW YORK, Oct. 18 – Incyte Genomics and Medarex said Thursday they would work together to develop and commercialize human antibody therapeutics.
Under the terms of the deal, Medarex and Incyte will share the preclinical and clinical development costs associated with developing antibody products. The two companies said they would also jointly sell and distribute products resulting from the collaboration.
Incyte of Palo Alto, Calif., said it would work from its database of transcribed genes, which includes over 600 patented full-length genes. Recently, Incyte has been expanding the claims of these patents to include the proteins encoded by gene transcripts as well as the antibodies to the proteins.
Medarex of Princeton, NJ, said it would apply its UltiMab Human Antibody Development System for the development of fully human monoclonal antibodies to the disease targets selected by Incyte from its database.
Financial terms of the deal were not disclosed.